Neurology, psychiatry, and primary care experts examine agitation associated with dementia due to Alzheimer's disease, from recognition and differential diagnosis through caregiver burden, non-pharmacologic strategies, and the two FDA-approved therapies, with practical guidance for coordinating care and shared decision-making across specialties.
In this Peer Exchange series, expert faculty discuss the evolving role of genetic testing in improving the recognition, diagnosis, and management of Dravet syndrome. The panel examines how earlier identification of genetic epilepsies can inform treatment decisions, and connect patients and families to valuable resources and support networks. They also review current treatment approaches, unmet needs associated with refractory disease, and the potential of emerging disease-modifying therapies to transform outcomes beyond seizure control in Dravet syndrome. Throughout the discussion, the importance of timely diagnosis, multidisciplinary care, and personalized management is emphasized as the field continues to advance.
A panel of MS specialists — Dr. Mitzi Joi Williams, Dr. Stephen Krieger, Dr. Benjamin Greenberg, and Dr. Riley Bove — explores anti-CD20 therapies in multiple sclerosis, covering updated diagnostic criteria, early high-efficacy treatment strategies, B-cell depletion, long-term safety monitoring, dosing, patient counseling, and family planning.
This Neurology Live Peer Exchange brings together a panel of neurology experts for a comprehensive discussion on CIDP, covering the full spectrum of the disease from epidemiology, diagnostic challenges, and disease variants to quality-of-life impact, evidence-based treatment options, and emerging targeted therapies. Panelists provide practical clinical guidance on individualizing immunoglobulin therapy, monitoring treatment response with objective outcome measures, setting realistic patient expectations, and optimizing long-term disease management, while underscoring the ongoing unmet needs for earlier diagnosis, reliable biomarkers, and more effective therapies.
Leading DMD specialists reviewed the evolving treatment landscape—including corticosteroids, gene therapy, and exon skipping—while emphasizing multidisciplinary care, individualized treatment decisions, real-world barriers, clinical trial opportunities, family support through advocacy organizations, and the critical importance of planning for pediatric-to-adult care transitions.
In this Neurology Times Peer Exchange series, expert panelists discuss key updates and clinical insights related to narcolepsy. The discussion focuses on reframing narcolepsy as a disorder of sleep-wake instability rather than simply excessive sleepiness, addressing the challenges of recognizing and diagnosing the condition in psychiatric populations, and providing practical guidance on pharmacologic treatment selection, polypharmacy, DEA scheduling considerations, and the importance of multidisciplinary, long-term care in optimizing patient outcomes across all age groups.
In this series, expert panelists discuss key updates and clinical insights related to secondary stroke prevention. The discussion focuses on identifying key risk factors for stroke recurrence to develop personalized prevention strategies. It further evaluates current standards of care alongside emerging clinical evidence regarding the role of Factor XIa inhibitors in secondary stroke prevention.
Panel of experts discuss the pathophysiology and disease progression of Duchenne Muscular Dystrophy before exploring the evolving treatment landscape, with a specific focus on newer therapeutic agents. Experts will conclude with insights on how these emerging therapies may influence future treatment strategies and reshape the management paradigm for patients with Duchenne Muscular Dystrophy.
This expert panel series centers on the complexities of identifying and monitoring disease progression in multiple sclerosis, examining limitations of traditional phenotypes and advancing the view of MS as a spectrum. The discussion highlights the need for nuanced clinical assessment, emerging diagnostic tools, and personalized strategies to detect and monitor progression, ultimately aiming to improve long-term outcomes for patients.
Panelists discuss how myasthenia gravis treatment is evolving from conventional symptomatic therapies toward targeted upstream and downstream approaches, emphasizing the importance of early intervention, shared decision-making with patients, achieving minimal symptom expression, and utilizing emerging therapies like FcRN inhibitors, complement inhibitors, and B-cell targeting agents to improve quality of life while reducing treatment burden.
Stuart Isaacson, MD; Daniel Kremens, MD, JD; Jill Ostrem, MD; Robert Hauser, MD, MBA, and Rajesh Pahwa, MD discuss how emerging therapeutic strategies and personalized treatment plans are transforming the management of off fluctuations in Parkinson's Disease, offering patients improved symptom control and quality of life.
A panel of experts discuss chronic inflammatory demyelinating polyneuropathy and its impact on patients’ quality of life as well as the current treatment landscape and emerging therapies for advancing CIDP treatment.
Fernando Pagan, MD; Jason Aldred, MD, FAAN; Maria Cristina Ospina, MD; and Rajeev Kumar, MD, discuss how to navigate the complexities of choosing the most effective pharmacological and nonpharmacological treatment regimens for patients with advanced Parkinson disease, considering the evolving challenges and needs as the disease progresses, the impact on quality of life, and the incorporation of emerging therapies such as continuous subcutaneous infusion systems.
Nicholas J. Silvestri, MD, FAAN; Ali A. Habib, MD; Neelam Goyal, MD; and Katherine Ruzhansky, MD, MS, explore the multifaceted aspects of generalized myasthenia gravis, from its clinical presentation and diagnosis to emerging targeted therapies, emphasizing the importance of personalized treatment approaches, discussing recent clinical trial data, and addressing ongoing challenges in both adult and pediatric populations.
Four healthcare professionals highlight variation in spasticity presentation and examine options available for management of spasticity. They discuss use of intrathecal baclofen (ITB) for treatment of severe spasticity, candidate patients who are likely to most benefit from ITB use, challenges and recent data with ITB use.
In a panel discussion, multiple sclerosis (MS) experts Stephen Krieger, MD; Heidi Crayton, MD; Jacqueline Nicholas, MD, PhD; Patricia Coyle, MD, and Enrique Alvarez, MD, PhD, share their insights on current MS therapies, aspirations for guideline revisions, the importance of shared decision-making, and the role of medium-efficacy therapy in the management of mild-to-moderate MS.
Lauren Elman, MD; Arun Varadhachary, MD, PhD; Thomas Crawford, MD; Julie Parsons, MD, and Crystal Proud, MD, provide valuable insights into the distinct clinical features of pediatric and adult SMA, the complex process of transitioning patients from pediatric to adult healthcare services, and the importance of effectively counseling patients on available treatment options and setting realistic expectations for treatment success.
Medical experts discuss the criticality of early intervention and evolving treatment strategies surrounding Alzheimer’s disease.
In this program, experts in sleep medicine focus on the treatment and management of excessive daytime sleepiness in narcolepsy. Together, they discuss patient selection criteria for available treatment options and guidance on switching therapies in narcolepsy.
A discussion between expert neurologists focuses on variability in presentation of myasthenia gravis (MG), guidance for diagnosis and personalization of care based on patient factors, and where targeted therapies can be utilized to control patient symptoms.
Expert thought leaders discuss current controversies, unmet needs, and opportunities in multiple sclerosis (MS) research and treatment.
Expert thought leaders review the latest data and trends regarding the use of neurofilament light chain and other biomarkers in MS diagnosis and treatment.
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
In an upcoming Peer Exchange program entitled “Dual-Orexin Receptor Antagonists for Treatment of Insomnia” Dr Paul Doghramji will moderate a conversation with physicians about this class of agents for treatment of insomnia and discuss other therapeutic advancements in the field.
Experts discuss Bruton's tyrosine kinase (BTK) inhibitors, which block the actions of B cells and may affect other cell types that can facilitate inflammation, recent key clinical data on BTK inhibitors in multiple sclerosis. and how to incorporate these novel agents into treatment plans once they become available.
Advanced practice providersdiscuss the who, what, where of biosimilars, a potential role of biosimilars in MS, and clinical data on biosimilars currently in development for MS. They provide insights into how to incorporate biosimilars into MS clinical practice.
Expert neurologists focus on generic disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). They discuss the expected benefit of generic DMTs and use in clinical practice. The panelists also review clinical cases and discuss possible treatment plans.
An expert neurology panel discusses diagnosis and treatment of dyskinesia in patients with Parkinson’s Disease. They discuss challenges in treating dyskinesia and finding a balance between OFF episodes and ON time, and current and emerging treatment options available for dyskinesia treatment.
Experts in neurology provide an overview of Neuromyelitis Optica Spectrum Disorder (NMOSD) and discuss recent approvals and updates in the treatment and management of this condition.
In this program, sleep experts will discuss the importance of timely and accurate diagnosis, recent approvals and available treatment options for the management of narcolepsy and excessive daytime sleepiness.
A panel of experts in dementia discusses the latest progress in the treatment of Alzheimer disease, and the various therapies that have progressed through the pipeline.